Phase II Ivonescimab Study Reports 70.1% Major Pathological Response in Resectable NSCLC – Akeso Biopharma

Coverage, in order

1. 4d ago
   
   OncoDaily obscure study randomized trial

   Phase II Ivonescimab Study Reports 70.1% Major Pathological Response in Resectable NSCLC – Akeso Biopharma

   Akeso Biopharma shared on LinkedIn: “Results from a Phase II clinical study evaluating ivonescimab in the perioperative treatment of resectable non-small cell lung cancer have been published in the journal

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.